SCHEMBL2209083

SCHEMBL2209083

CC1(C)CN(c2c(Cl)ccc3c2CCN(C(=O)C(F)(F)F)CC3)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 5/20 0.43
ESR2 Q92731 5/20 0.43
NOTUM Q6P988 3/20 0.35
HDAC6 Q9UBN7 2/20 0.34
PKM P14618 1/20 0.33
ACKR3 P25106 1/20 0.33
CYP11B2 P19099 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
PDK2 Q15119 1/20 0.31
ABHD6 Q9BV23 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
ADRA2A P08913 1/20 0.31
CYP2D6 P10635 1/20 0.31
ADRA2B P18089 1/20 0.31
ADRA2C P18825 1/20 0.31
ADRA1D P25100 1/20 0.31
ADRA1A P35348 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2209332 0.85 ESR1 (0.47) ESR1ESR2NOTUMPKMACKR3
SCHEMBL2209263 0.82 ESR1 (0.44) ESR1ESR2NOTUMPKMACKR3
SCHEMBL506186 0.79 ESR1 (0.50) ESR1ESR2NOTUMHDAC6PKM
SCHEMBL2208316 0.78 ESR1 (0.40) ESR1ESR2NOTUMACKR3LMNA
SCHEMBL506164 0.77 ESR1 (0.55) ESR1ESR2NOTUMHDAC6PKM
SCHEMBL2258012 0.77 ESR1 (0.48) ESR1ESR2NOTUMHDAC6PKM
SCHEMBL507139 0.76 ESR1 (0.53) ESR1ESR2NOTUMHDAC6PKM
SCHEMBL2205972 0.76 ESR1 (0.37) ESR1ESR2NOTUMPKMCYP11B2
SCHEMBL3965337 0.75 ESR1 (0.48) ESR1ESR2NOTUMHDAC6PKM
SCHEMBL2255041 0.74 ESR1 (0.48) ESR1ESR2NOTUMPKMACKR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1924578-B1 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS LILLY CO ELI (US) 2013-11-06 EP disclosed
US-7981882-B2 e.g. 7-Chloro-3-(2,2,2-trifluoroacetyl)-6-trifluoromethanesulfonyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine; antidepressant, anxiolytic agent; obesity, obsessive/compulsive disorder ELI LILLY AND COMPANY (US) 2011-07-19 US disclosed
US-20080214520-A1 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists ELI LILLY AND COMPANY 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214520-A1 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists HTR2C, HTR3B, HTR1A ESR1 300/4885ESR2 261/4885NOTUM 3896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.